v2.4.0.8
Segment reporting (Tables)
 12 Months Ended
Dec. 31, 2013
Summary of Segment Net Revenues, Segment Operating Income Loss and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes

The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:

Year ended December 31,
2013 2012 2011

Segment revenues:

U.S. dialysis and related lab services

Patient service revenues:

External sources

 $ 7,998,692 $ 7,299,032 $ 6,462,811

Intersegment revenues

 34,080 17,786 11,141

Total dialysis and related lab services revenues

 8,032,772 7,316,818 6,473,952

Less: Provision for uncollectible accounts

 (281,146 ) (233,580 ) (190,234 )

Net dialysis and related lab services patient service revenues

 7,751,626 7,083,238 6,283,718

Other revenues(1)

 12,600 11,447 11,019

Total net dialysis and related lab services revenues

 7,764,226 7,094,685 6,294,737

HCP

HCP revenues:

External sources

 $ 2,919,964 $ 419,431 $ —

Intersegment revenues

 250 — —

Total HCP capitated revenues

 2,920,214 419,431 —

Net patient service revenues

 220,251 34,407 —

Other revenues

 55,723 23,552 —

Total revenues

 $ 3,196,188 $ 477,390 $ —

Other – Ancillary services and strategic initiatives

Net patient service revenues

 $ 75,852 $ 16,824 $ 7,730

Capitated revenues

 67,351 61,906 45,133

Other external sources

 694,763 553,261 395,347

Intersegment revenues

 13,916 10,481 5,796

Total ancillary services and strategic initiatives revenues

 851,882 642,472 454,006

Total net segment revenues

 11,812,296 8,214,547 6,748,743

Elimination of intersegment revenues

 (48,246 ) (28,267 ) (16,937 )

Consolidated net revenues

 $ 11,764,050 $ 8,186,280 $ 6,731,806

Segment operating margin (loss):(2)

U.S. dialysis and related lab services

 $ 1,211,540 $ 1,378,241 $ 1,235,869

HCP

 385,253 66,930 —

Other—Ancillary services and strategic initiatives

 (38,595 ) (64,877 ) (34,105 )

Total segment margin

 1,558,198 1,380,294 1,201,764

Reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:

Contingent earn-out obligation adjustment

 56,977 — —

Corporate support costs(3)

 (65,041 ) (52,457 ) (47,051 )

Transaction expenses

 — (30,753 ) —

Consolidated operating income

 1,550,134 1,297,084 1,154,713

Debt expense

 (429,943 ) (288,554 ) (241,090 )

Debt refinancing and redemption charges

 — (10,963 ) —

Other income

 4,787 3,737 2,982

Consolidated income from continuing operations before income taxes

 $ 1,124,978 $ 1,001,304 $ 916,605

(1) Includes management fees for providing management and administrative services to dialysis centers in which the Company owns a minority equity investment or which are wholly-owned by third parties.
(2) Certain costs previously reported in the ancillary services and strategic initiatives have been reclassified to U.S. dialysis and related lab services to conform to the current year presentation.
(3) Corporate support costs also include $7,721 of an adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions.
Summary of Assets by Segment

Summary of assets by segment is as follows:

December 31,
2013 2012

Segment assets

U.S. dialysis and related lab services

 $ 10,248,993 $ 9,351,466

HCP

 6,265,767 6,228,403

Other—Ancillary services and strategic initiatives(1)

 584,117 434,764

Consolidated assets

 $ 17,098,877 $ 16,014,633

(1) Includes approximately $26 million and $13 million, respectively, of net property and equipment related to the Company’s international operations.